Liraglutide is a glucagon-like peptide-1 receptor agonist
It outlines the multifaceted anticancer mechanisms of bioactive compoundssuch as polyphenols, carotenoids, omega-3 fatty acids, phytosterols, alkaloids, isothiocyanates, polysaccharides, phenolic acids, flavonols, and amide-bearing compoundswhich include antioxidant and anti-inflammatory activities, induction of apoptosis and autophagy, modulation of the tumor microenvironment, interference with cell cycle regulation and signaling pathways, and regulation of cancer-related microRNA expression
WADA's prohibited list includes growth hormone, growth hormone-releasing hormone analogues, growth hormone secretagogues and related substances
Mechanism of Action BPC-157 works through several interconnected pathways
Despite these advances, several controversies remain unresolved